Abstract

 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses upadacitinib (Rinvoq) oral extended-release tablets, 15 mg and 30 mg.
 Indication: For the treatment of adults and adolescents 12 years of age and older with refractory, moderate to severe atopic dermatitis (AD) who are not adequately controlled with a systemic treatment (e.g., a steroid or biologic), or when the use of such therapies is inadvisable. Upadacitinib (Rinvoq) can be used with or without topical corticosteroids.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.